Project Grant R43AI192167
Award Date 7/21/26
Completion Date 1/31/27
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $246,000 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a hidden Markov modeling framework that characterizes the full clinical progression of Clostridioides difficile infection using patient-level electronic health data. The project addresses gaps in current analytic approaches that treat CDI as a single symptomatic...
- The National Institute of Allergy and Infectious Diseases awarded $182,424 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on October 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the effect of epithelium association and toxin gene expression on Clostridioides difficile disease severity. The research addresses the mechanisms driving disease severity in C. difficile infection (CDI), the most common...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $437,541 to Virginia Polytechnic Institute & State University on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antisense therapeutics targeting Clostridioides difficile infection. The research focuses on designing antisense oligomers, including peptide nucleic acids, to suppress...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Iowa $684,797 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the genetic requirements for lipoteichoic acid synthesis in Clostridioides difficile. The research addresses antibiotic resistance in C. difficile, the leading cause of hospital-acquired infectious diarrhea. Current treatment options...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $609,185 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a physics-informed machine learning model for elucidating the therapeutic mechanisms of bacterial therapeutics against Clostridium difficile infection. The funded work centers on creating a Neural Species Mediator model to systematically understand how living bacterial therapeutics function in the...
- The National Institute of Allergy and Infectious Diseases awarded $430,024 to the University of Pittsburgh on July 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intestinal interactions between Clostridioides difficile and Clostridium perfringens and their impact on gastrointestinal disease pathology. The research addresses the epidemiologic association between these two clostridial pathogens, which frequently co-occur in diarrheic feces of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $242,250 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop prognostic biomarkers for invasive candidiasis. The research addresses the urgent clinical need to identify patients at high risk of severe outcomes from invasive candidiasis—which causes up to 40 percent mortality in solid organ transplant recipients—and to predict treatment response. The project...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $151,040 on January 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize the unique cell division machinery of Clostridioides difficile, a major nosocomial pathogen. The research addresses a critical gap in understanding bacterial cell division. Unlike model organisms studied over decades,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $769,354 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate spore germination machinery in Clostridioides difficile and optimize a class of antibiotics called oxadiazoles as spore germination inhibitors. The research addresses recurrent C. difficile infections, which occur in approximately 25 percent of patients and represent a significant source of...